Antinociceptive Properties of Protein C in a Model of Inflammatory Hyperalgesia in Rats

Summary

We investigated the role of human protein C in an animal model of inflammatory hyperalgesia. Pain was induced by intraplantar injection of carrageenan (3 mg) into the hind paw of rats. The pain threshold was measured by exerting increasing amounts of pressure (in mmHg) on the paw until a struggle reaction was observed. Protein C (8-800 IU/kg) was administered intravenously immediately after carrageenan. Controls received either intraplantar injections of saline (100 µ1) instead of carrageenan or carrageenan alone. Effects on pain threshold were expressed in percent of the pretreatment value. Carrageenan alone lowered the mean pain threshold after 3 h to 33.2 ± 2.2% of the pretreatment level. Addition of protein C resulted in a dose-dependent rise in pain threshold towards the level observed in control animals treated with saline instead of carrageenan (pain threshold after 800 IU/kg protein C = 62.9 ± 2.3% of pretreatment level), demonstrating an antinociceptive effect. Protein C had no effect in animals not preconditioned with intraplantar carrageenan. Thus protein C clearly antagonized the inflammatory pain induced by carrageenan. The antinociceptive action of protein C was antagonized by injection of a monoclonal antibody against protein C, providing additional evidence that the effect was protein C-mediated.

• References

• 1 Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264: 4743-4746
• 2 Marlar RA, Kleiss AJ, Griffin JH. Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. Blood 1982; 59: 1067-1072
• 3 Dreyfus M, Magny JF, Bridey F, Schwarz HP, Planché C, Dehan M, Tchernia G. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N Engl J Med 1991; 325: 1565-1568
• 4 Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68: 1370-1373
• 5 Schramm W, Spannagl M, Bauer KA, Rosenberg RD, Birkner B, Linnau Y, Schwarz HP. Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate. Arch Dermatol 1993; 129: 753-756
• 6 Randall LO, Selitto JJ. A method for measurement of analgesic activity in inflamed tissue. Arch Int Pharmacodyn 1957; 111: 409-419
• 7 Winter CA, Risley EA, Nuss GW. Carrageenin-induced edema in hind paw of the rat as an assay for antiinflammatory drugs. Proc Soc Exp Biol Med 1962; 111: 544-547
• 8 Long GL, Tomczak JA, Rainville IR, Dreyfus M, Schramm W, Schwarz HP. Homozygous type I protein C deficiency in two unrelated families exhibiting thrombophilia related to Ala₁₃₆→Pro or Arg₂₈₆→His mutations. Thromb Haemost 1994; 72: 526-533
• 9 De Stefano V, Mastrangelo S, Schwarz HP, Pola P, Flore R, Bizzi B, Leone G. Replacement therapy with a purified protein C concentrate during initiation of oral anticoagulation in severe protein C congenital deficiency. Thromb Haemost 1993; 70: 247-249
• 10 Gerson WT, Dickerman JD, Bovill EG, Golden E. Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: Treatment with protein C concentrate. Pediatrics 1993; 91: 418-422
• 11 Gruber A, Griffin JH, Harker LA, Hanson SR. Inhibition of platelet-dependent thrombus formation by human activated protein C in a primate model. Blood 1989; 73: 639-642
• 12 Heeb MJ, Rosing J, Bakker HM, Fernandez JA, Tans G. Protein S binds to and inhibits factor Xa. Proc Natl Acad Sci USA 1994; 91: 2728-2732
• 13 Gruber A, Mori E, del Zoppo GJ, Waxman L, Griffin JH. Alteration of fibrin network by activated protein C. Blood 1994; 83: 2541-2548
• 14 Hubbard AR. Standardization of protein C in plasma: Establishment of an international standard. Thromb Haemost 1988; 59: 464-467
• 15 Steams DJ, Kurosawa S, Sims PJ, Esmon NL, Esmon CT. The interaction of a Ca²⁺-dependent monoclonal antibody with the protein C activation peptide region. J Biol Chem 1988; 263: 826-832
• 16 Gruber A, Griffin JH. Direct detection of activated protein C in blood from human subjects. Blood 1992; 79: 2340-2348
• 17 Conard J, Bauer KA, Gruber A, Griffin JH, Schwarz HP, Horellou MH, Samama MM, Rosenberg RD. Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiency. Blood 1993; 82: 1159-1164
• 18 Ono M, Fujiwara H, Okafuji T, Enjoh T, Nawa K. Recombinant rat protein C: Comparative studies of structure, function and synthesis with plasma protein C. Thromb Haemost 1994; 71: 54-61
• 19 Rang HP, Bevan S, Dray A. Chemical activation of nociceptive peripheral neurones. Br Med Bull 1991; 47: 534-548
• 20 Kirchhoff C, Jung S, Reeh PW, Handwerker HO. Carrageenan inflammation increases bradykinin sensitivity of rat cutaneous nociceptors. Neuroscience Letters 1990; 111: 206-210
• 21 Woolf CJ. Generation of acute pain: Central mechanisms. Br Med Bull 1991; 47: 523-533
• 22 Taylor FB, Chang A, Esmon CT, D’Angelo A, Vigano-D’Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusions in the baboon. J Clin Invest 1987; 79: 918-925
• 23 Grey S, Hau H, Salem HH, Hancock WW. Selective effects of protein C on activation of human monocytes by lipopolysaccharide, interferon-γ, or PMA: Modulation of effects on CD1 lb and CD14 but not CD25 or CD54 induction. Transplant Proc 1993; 25: 2913-2914
• 24 Grinnell BW, Herzmann RB, Yan SB. Human protein C inhibits selectin- mediated cell adhesion: Role of unique fucosylated oligosaccharide. Glycobiology 1994; 4: 221-225